Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- Dow opens at record high led by oil, bank stocks
- Oil tops $55 for first time in 16 months as OPEC deal fuels buying
- Consolidated Communications (CNSL) to Acquire FairPoint Communications (FRP) in $1.5B Deal
- Wall St. stock futures fall after Italy referendum
- Pre-Open Stock Movers 12/05: (FRP) (GMED) (CHK) Higher; (CERC) (HDSN) (MRVL) Lower (more...)
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kyocera Medical (KYO) Granted FDA 510(k) Clearance for Initia Total Hip System
- Zogenix (ZGNX) Data Shows Effectiveness and Cardiovascular-Related Safety for ZX008
- ATARA Biotherapeutics (ATRA) Announces Encouraging Data from CMV-CTL Phase 2 in CMV-Specific CTLs
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!